These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16212139)

  • 41. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
    Cryer B; Bauer DC
    Mayo Clin Proc; 2002 Oct; 77(10):1031-43. PubMed ID: 12374247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies.
    Hawkey CJ; Talley NJ; Scheiman JM; Jones RH; Långström G; Naesdal J; Yeomans ND;
    Arthritis Res Ther; 2007; 9(1):R17. PubMed ID: 17391505
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tolerability and compliance with risedronate in clinical practice.
    Hamilton B; McCoy K; Taggart H
    Osteoporos Int; 2003 May; 14(3):259-62. PubMed ID: 12730745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiperistaltic effect and safety of L-menthol sprayed on the gastric mucosa for upper GI endoscopy: a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Hiki N; Kaminishi M; Yasuda K; Uedo N; Honjo H; Matsuhashi N; Hiratsuka T; Sekine C; Nomura S; Yahagi N; Tajiri H; Suzuki H
    Gastrointest Endosc; 2011 May; 73(5):932-41. PubMed ID: 21353674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies.
    Hawkey CJ; Svedberg LE; Naesdal J; Byrne C
    Clin Drug Investig; 2009; 29(10):677-87. PubMed ID: 19715384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.
    Steinbuch M; D'Agostino RB; Mandel JS; Gabrielson E; McClung MR; Stemhagen A; Hofman A
    Regul Toxicol Pharmacol; 2002 Jun; 35(3):320-6. PubMed ID: 12202047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of dosing regimen on the pharmacokinetics of risedronate.
    Mitchell DY; Heise MA; Pallone KA; Clay ME; Nesbitt JD; Russell DA; Melson CW
    Br J Clin Pharmacol; 1999 Oct; 48(4):536-42. PubMed ID: 10583024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of risedronate on osteoarthritis of the knee.
    Iwamoto J; Takeda T; Sato Y; Matsumoto H
    Yonsei Med J; 2010 Mar; 51(2):164-70. PubMed ID: 20191005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risedronate gastrointestinal absorption is independent of site and rate of administration.
    Mitchell DY; Eusebio RA; Dunlap LE; Pallone KA; Nesbitt JD; Russell DA; Clay ME; Bekker PJ
    Pharm Res; 1998 Feb; 15(2):228-32. PubMed ID: 9523308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women.
    Lanza FL; Rack MF; Li Z; Krajewski SA; Blank MA
    Aliment Pharmacol Ther; 2000 Dec; 14(12):1663-70. PubMed ID: 11121916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of cimetidine on gastrointestinal symptoms in patients taking nonsteroidal anti-inflammatory drugs. A large double-blind placebo controlled study.
    Rugstad HE; Giercksky KE; Husby G; Holme I
    Scand J Rheumatol; 1994; 23(4):177-82. PubMed ID: 8091142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers.
    Mitchell DY; Eusebio RA; Sacco-Gibson NA; Pallone KA; Kelly SC; Nesbitt JD; Brezovic CP; Thompson GA; Powell JH
    J Clin Pharmacol; 2000 Mar; 40(3):258-65. PubMed ID: 10709154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Loxoprofen Hydrogel Transdermal Patch Versus Loxoprofen Tablet in Chinese Patients with Myalgia: A Double-Blind, Double-Dummy, Parallel-Group, Randomized, Controlled, Non-Inferiority Trial.
    Zhao D; Chen Z; Hu S; Lin J; Shao Z; Wang G; Xiao W; Zheng Y; Zhang Z; Shi Y; Li Z
    Clin Drug Investig; 2019 Apr; 39(4):369-377. PubMed ID: 30725315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Upper gastrointestinal adverse events and cyclical etidronate.
    van Staa T; Abenhaim L; Cooper C
    Am J Med; 1997 Dec; 103(6):462-7. PubMed ID: 9428828
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial.
    Kawasaki T; Kurosawa H; Ikeda H; Kim SG; Osawa A; Takazawa Y; Kubota M; Ishijima M
    J Bone Miner Metab; 2008; 26(3):279-87. PubMed ID: 18470670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of endoscopy-negative NSAID-induced upper gastrointestinal symptoms with cimetidine: an international multicentre collaborative study.
    Bijlsma JW
    Aliment Pharmacol Ther; 1988; 2 Suppl 1():75-83. PubMed ID: 2979286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic review for evaluation of tolerability of nonsteroidal antiinflammatory drugs in osteoarthritis patients in Japan.
    Uemura S; Ochi T; Sugano K; Makuch RW
    J Orthop Sci; 2003; 8(3):279-87. PubMed ID: 12768466
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analgesic and chondroprotective effects of risedronate in osteoarthritis assessed by electroalgometry and measurement of collagen type II fragments in urine.
    Fujita T; Ohue M; Fujii Y; Miyauchi A; Takagi Y
    J Int Med Res; 2008; 36(5):932-41. PubMed ID: 18831886
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of renal function on risedronate pharmacokinetics after a single oral dose.
    Mitchell DY; St Peter JV; Eusebio RA; Pallone KA; Kelly SC; Russell DA; Nesbitt JD; Thompson GA; Powell JH
    Br J Clin Pharmacol; 2000 Mar; 49(3):215-22. PubMed ID: 10718776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Dansereau RJ; Vincent RM; Wenderoth D; Hathaway S; Li Z; Spiller RC
    Int J Pharm; 2001 Jul; 222(2):295-303. PubMed ID: 11427359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.